Clinical Setback

A less likely but realistic outcome is that the treated patient has a serious inflammatory reaction, treatment failure, or pathogen rebound. Because this would be tied to a first-in-human AI-designed phage case, it would hurt sentiment toward synthetic-biology and phage-therapy developers, though it would not create a broad macro shock.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.